AbbVie Achieves 60% Progression Risk Reduction for Etentamig in Phase 3 Multiple Myeloma Trial

AbbVie's etentamig has delivered statistically significant results across both dual primary endpoints in a Phase 3 multiple myeloma trial, cutting the risk of disease progression by 60%, data that will sharpen BLA filing timelines and force manufacturing teams to confront the scale-up demands specific to bispecific antibody modalities.

The trial measured progression-free survival and overall response rate as co-primary endpoints, and AbbVie confirmed that differences against the comparator arm were statistically significant. For drug development and regulatory affairs leads tracking the hematologic oncology pipeline, the dual-endpoint achievement carries particular weight: regulators at FDA and EMA have increasingly required robust progression-free survival data, not response rate alone, before granting accelerated or full approval in relapsed/refractory myeloma indications.

Etentamig is a bispecific antibody, a modality that presents distinct process validation and sterility assurance challenges compared with conventional monoclonal antibodies. Manufacturing teams preparing for commercial-scale production will need to address the heightened complexity of bispecific assembly, purification train design, and fill-finish operations under 21 CFR Part 211 and applicable ICH Q10 quality system requirements. Yield consistency and comparability across clinical and commercial batches will be a central focus of any Chemistry, Manufacturing, and Controls package submitted alongside a BLA.

The bispecific antibody class has accumulated a growing evidence base in hematologic oncology over the past two years, with several agents now approved or under rolling review. Etentamig's Phase 3 data adds a late-stage, randomized dataset to that body of evidence, a meaningful step beyond the single-arm studies that supported earlier entrants in this space. Regulatory teams will note that a randomized Phase 3 design typically supports a standard approval pathway rather than accelerated approval, which has implications for label negotiations and post-marketing commitment scope.

The BLA filing timeline has not been publicly disclosed, but the availability of statistically significant dual-endpoint data from a Phase 3 study positions AbbVie to initiate submission preparation, with manufacturing readiness and GMP compliance documentation among the critical path items.

Source: Media4Growth via Indian Pharma Post, 3 September 2026.